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ABSTRACT 
Background and aims: Hypoxia can induce inflammation in the gastrointestinal tract. 
However, the impact of hypoxia on the course of inflammatory bowel disease (IBD) is poorly 
understood. We aimed to evaluate whether flights and/or journeys to regions lying at an 
altitude of > 2,000 m above the sea level are associated with flare-ups within 4 weeks of the 
trip. 
Methods: IBD patients with at least one flare-up during a 12-month observation period were 
compared to a group of patients in remission. Both groups completed a questionnaire.  
Results: A total of 103 IBD patients were included (43 with Crohn's disease (CD): mean 
age 39.3 ± 14.6 years; 60 with ulcerative colitis (UC): mean age 40.4 ± 15.1 years). Fifty-
two patients with flare-ups were matched to 51 patients in remission. IBD patients 
experiencing flare-ups had more frequently undertaken flights and/or journeys to regions > 
2,000 m above sea level within four weeks of the flare-up when compared to patients in 
remission (21/52 [40.4 %] vs. 8/51 [15.7 %], p = 0.005). Conclusions: Journeys to high 
altitude regions and/or flights are a risk factor for IBD flare-ups occurring within 4 weeks of 
travel. 
245 words  
Key words: Crohn’s disease, ulcerative colitis, inflammatory bowel disease, hypoxia, hypoxic 
stress  
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INTRODUCTION 
     Inflammatory bowel disease (IBD) is a chronic, often debilitating intestinal disorder.1,2,3 
The etiology of IBD has not yet been fully elucidated; however, results of multiple studies 
point to a role of dysregulated innate and adaptive immune responses to intestinal bacteria.4 
Over the last few years, several studies have demonstrated that hypoxia can induce 
inflammation. Plasma levels of several inflammatory markers, such as interleukin-6, 
interleukin-1 receptor antagonist, and C-reactive protein, were found to be increased in 
healthy volunteers spending 68 hours at an elevation of 3,400 m above the sea level.5 In 
murine models, exposure to normobaric hypoxia leads to tissue accumulation of 
polymorphonuclear neutrophils, increased serum levels of pro-inflammatory cytokines, and 
vascular leakage.6,7,8,9,10 Hypoxia is a hallmark of many disease states and is known as a 
potent inflammatory stimulus. For example, ischemia in organ grafts increases the risk of 
inflammation in the graft with consecutive graft failure or rejection.11 While hypoxia may lead 
to inflammation, inflammation can also lead to hypoxia in the tissue via different 
mechanisms, such as edema, vasoconstriction or production of reactive oxygen species 
triggering local oxygen depletion.12 A steep oxygen concentration gradient, a consequence 
of the close proximity of the richly perfused oxygen bed to the anoxic bowel lumen, 
contributes to the unique oxygenation profile of the gut. Several studies have examined the 
role of hypoxia in mucosal tissue damage in IBD and shown that surgical specimens taken 
from patients with active CD and UC were found to contain elevated levels of hypoxia-
inducible factors (HIF)-1α and HIF-2α.13,14 These two factors trigger the expression of genes 
that are responsible for the maintenance of intestinal epithelial barrier function.13,14 
Furthermore, NF-κB also appears to play a role in response to stress, such as hypoxia, as 
activation of NF-κB in intestinal epithelial cells in response to gut ischemia-reperfusion in 
mice leads to increase in the production of proinflammatory cytokine tumor necrosis factor 
(TNF) and simultaneous attenuation of intestinal epithelial apoptosis.15 
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     The fraction of oxygen in the air is 21 %, and barometric pressure at sea level is 
approximately 760 mm Hg. During airplane flights, the oxygen partial pressure in the cabin 
decreases, which leads to a reduction in the percentage of oxygen-saturated hemoglobin in 
the blood.16 International laws demand that the cabin pressure must not be lower than the 
one measured at 8,000 ft (2,438 m; barometric pressure is 564 mm Hg).17 A study 
evaluating the cabin pressure during 240 flights revealed that the cabin pressure ranged 
between the one detected at 5,000 ft (1,524 m; barometric pressure is 632 mm Hg) to that 
measured at 8,000 ft with a mean value corresponding to a pressure measured at 6,214 ft 
(1,894 m; barometric pressure is 604 mm Hg).18 Breathing at 8,000 ft or at 5,000 ft is 
equivalent to breathing a hypoxic mixture with an oxygen fraction of 15.1 % or 17.1 % at sea 
level, respectively. Healthy subjects exposed to a hypoxic mixture of gases with 15.1 % or 
17.1 % oxygen had a mean arterial oxygen pressure of 53 or 64 mm Hg (normal values 65 – 
100 mm Hg) and mean arterial oxygen saturation of 85 % or 91 %, respectively.19 While 
such decreases of arterial oxygen saturation are tolerated well by healthy subjects, this 
hypobaric hypoxia during aircraft travel may cause difficulties for patients with pulmonary 
disease.16 Clinical data evaluating a potential impact of hypobaric hypoxia on disease 
activity in IBD is currently lacking. Therefore, we evaluated whether reduced oxygen partial 
pressure during aircraft travel and/or journeys to regions lying at an altitude of > 2,000 m 
above the sea level is associated with changes in clinical disease activity in four weeks 
following the trip. 
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MATERIALS AND METHODS 
Patients 
    In this study, a questionnaire-based survey was conducted. IBD patients from in- and 
outpatient clinics of three Swiss tertiary hospitals (Triemli Zurich, University Hospital Zurich, 
and Centre Hospitalier Universitaire Vaudois) were recruited. The study was conducted as a 
project of the Swiss Inflammatory Bowel Disease Cohort Study and was approved by the 
Ethics Committees (SNSF 33CSC0_134274).20 Prior to inclusion into the study, written 
informed consent was obtained from all patients. 
 
Methods 
     For the purposes of the survey, IBD patients with at least one flare-up episode in the 
observation period from September 1st, 2010 to August 31st, 2011 were compared to IBD 
patients, who were in clinical remission during the same observation period.     Data were 
obtained by the means of a structured questionnaire and review of medical charts. The 
questionnaire contained items addressing the following topics: demographics, medical 
history, medication history and the history of aircraft travel and/or high-altitude journeys (> 
2,000 m above sea level), the duration of the trip(s) (in hours), date and flight destination, as 
well as details on travel habits within 4 weeks of the flare. CD patients were categorized into 
the groups with different disease location based on Montréal classification, where L1 
corresponds to disease in the terminal ileum, L2 corresponds to disease in the colon, L3 
corresponds to ileocolonic disease, and L4 corresponds to isolated disease in the upper 
gastrointestinal tract.21 UC patients were categorized into the groups with different disease 
location according the Montréal classification, where E1 corresponds to rectal disease, E2 
corresponds to left-sided colitis, and E3 corresponds to an extensive colitis. 
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     Inclusion criteria for enrollment of CD and UC patients with flare-up episode(s) into this 
study were as follows: age 18 - 80 years, at least one flare-up episode in the observation 
period between September 1st, 2010 and August 31st, 2011. It was mandatory that the 
occurrence of a flare-up episode as reported by the patient was verified by a physician in the 
course of a clinical examination. Furthermore, in order to attribute a flare-up episode to IBD, 
an infectious etiology had to be excluded. For this reason, microbiological workup of fecal 
samples for known infectious agents, such as Salmonella, Shigella, Campylobacter spp., 
test for presence of Clostridium difficile toxin in feces, examination of 3 different fecal 
samples for parasites, and evaluation of biopsies for cytomegalovirus were carried out. No 
routine tests for other viral intestinal infections were performed. Inclusion criteria for 
enrollment of CD and UC patients in clinical remission into the study were as follows: age 18 
- 80 years, maintenance of clinical remission during the observation period between 
September 1st, 2010 and August 31st, 2011. Exclusion criteria for a group with flare-up 
episode(s) and for a group in remission were as follows: perianal Crohn’s disease, positive 
results of microbiological workup of fecal samples for known infectious agents during a 
flare-up episode, and any cardio-pulmonary condition affecting oxygen hemoglobin 
saturation, such as chronic obstructive pulmonary disease. 
 
Definitions 
     Clinical activity in CD patients was assessed using the Harvey Bradshaw Index (HBI).22 
In 2006, using regression modeling, Best et al. reported that a one-point increase in a value 
of HBI corresponds to a 27-point increase in the value of CDAI.23 For the purposes of this 
manuscript, the following definitions were applied: a value of HBI from 0 to 4 points indicates 
clinical remission (corresponds to a mean ± SD CDAI values of 26 ± 26 to 134 ± 39, 
respectively); a value of HBI from 5 to 7 points indicates mild disease (corresponds to a 
mean ± SD CDAI values of 161 ± 42 to 216 ± 49, respectively); a value of HBI from 8 to 15 
indicates moderate disease (corresponds to a mean ± SD CDAI values of 243 ± 52 to 432 ± 
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75, respectively); and a value of HBI ≥ 16 indicates severe disease (corresponds to a mean 
± SD CDAI value of ≥ 459 ± 78). A flare-up episode in CD patients was defined as a rise in 
HBI value of ≥ 4 points, which corresponds to a CDAI increase of ≥ 108 points. 
     Clinical activity in UC patients was assessed using the Rachmilewitz Index, which ranges 
from 0 to 29 points.24 A value from 0 to 4 points indicates clinical remission; a value from 5 
to 10 points corresponds to mild activity; a value from 11 to 17 indicates moderate activity; 
and a value of ≥ 18 points indicates highly active disease.25 A flare-up in UC patients was 
defined as an increase in the Rachmilewitz Index value of ≥ 5 points. 
     Patients with clinical IBD flare-up(s) underwent clinical, endoscopic and laboratory 
examinations (see inclusion and exclusion criteria above). Only those patients with an 
increase in clinical activity attributed to IBD were included into the study. 
 
 
Statistical analysis 
     Data from questionnaires were entered into EpiData version 1.1.2. All statistical analyses 
were performed with the statistical program STATA (version 12, College Station, Texas, 
USA). A priori power analysis revealed that a sample size of 76 patients (38 patients for the 
group experiencing flare-up episode(s) and 38 patients for the group in remission) would 
have 90 % power to detect a difference in the rate of trips with the aircraft and/or to regions 
lying at an altitude of > 2,000 m above the sea level between these two groups. We 
expected a yearly rate of 20 trips by aircraft and/or to regions lying at an altitude of > 2,000 
m above the sea level for the group experiencing flare-up episode(s) (standard deviation = 
8) and a yearly rate of 15 trips for the group in remission (standard deviation = 5). Data 
distribution was analyzed using Normal-QQ-Plots. Results of quantitative data are presented 
as either mean ± SD and range (for parametric data) or median plus interquartile range 
(IQR) (for non-parametric data). Categorical data were summarized as the percentage of 
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the group total. Differences in quantitative data distributions were assessed by the Student’s 
t-test (for parametric data) and by the Wilcoxon rank-sum test (in case of non-parametric 
data). The Kruskal-Wallis test was used for comparison of more than 2 independent 
samples. A p-value of < 0.05 was considered statistically significant.  
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RESULTS 
Patient characteristics 
     One hundred forty two IBD patients were screened. Of these, 103 (72.5 %) patients were 
included in the study. Forty-three patients had Crohn's disease (CD) (mean age 39.3 ± 14.6 
years old), and 60 patients suffered from ulcerative colitis (UC) (mean age 40.4 ± 15.1 years 
old). Thirty nine patients were excluded for the following reasons: a flare-up episode was not 
confirmed by a physician or a definition of flare-up episode was not met (24), presence of 
perianal CD (4), unwillingness to participate (3), presence of infectious agents, such as 
ameba (1), Giardia lamblia (2), C. difficile (1), Campylobacter jejuni (2), and presence of 
chronic obstructive pulmonary disease (2).  
     Fifty-two patients experiencing flare-up episodes were compared to 51 patients in clinical 
remission. The background demographic characteristics and disease characteristics of the 
two groups are shown in Table 1. No difference between the two groups regarding smoking 
habits and level of regular physical activity was detected. For the purposes of this study, 
regular physical activity was defined as at least two 30-minute sessions of workout per 
week. CD patients suffered from 1.5 ± 1.1 flare-up episodes and UC patients from 2 ± 1.8 
flare-up episodes in the observation period. Details on flare-up episode duration, severity, 
and treatment strategies are shown in Table 2. No association between a season or a 
month of the year and a frequency of IBD flare-up episodes was observed (data not shown). 
 
Medication history 
     The medication history of patients with flare-up episodes and patients in remission is 
presented in Table 3. Aminosalicylates, immunomodulators and anti-TNF drugs were 
prescribed at similar frequencies to CD and UC patients with and without flare-up episodes 
during the observation period. As expected, systemic steroids were significantly more 
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frequently taken by CD and UC patients experiencing flare-ups during the study period. 
NSAIDs and antibiotics were prescribed at similar frequencies to both groups of patients. 
 
Mild hypoxic stress was more frequent in patients with flare-up episodes compared 
to controls  
     Mild hypoxic stress was defined as aircraft travel and/or journeys to regions lying at an 
altitude of > 2,000 m above the sea level. Details regarding the occurrence of mild hypoxic 
stress in the two groups during the observation period between September 1st, 2010 and 
August 31st, 2011 are presented in Table 4. Twenty one patients in the group experiencing 
flare-up episodes (n = 52) traveled by aircraft and/or journeyed to regions lying at an altitude 
of > 2,000 m above the sea level within 4 weeks of occurrence of the flare-up when 
compared to 8 patients in the IBD group that were in clinical remission (40.4 % vs. 15.7 %, p 
= 0.005). These findings are illustrated in Figure 2. When a comparison between subgroups 
of IBD patients was made, 8/21 CD patients who experienced flare-up episode(s) had 
travelled by airplane or to high altitude regions when compared to 2/22 CD patients in 
clinical remission (38.1 % vs. 9.1 %, p = 0.024). In UC patients experiencing flare-up 
episodes, a trend for more frequent aircraft travel and journeys to higher regions was 
observed (13/31 vs. 6/29, p = 0.077). 
     A detailed analysis of the frequency, duration, and destination of the flights is provided in 
Table 5. IBD patients experiencing flare-up episodes more frequently travelled by aircraft 
when compared to IBD patients in remission (14/52 vs. 5/51, p = 0.025). On average, IBD 
patients experiencing flare-up episodes traveled 6.2 ± 4.2 hours when compared to 4 ± 4.1 
hours in the IBD group in remission (p = 0.368). 
     We also analyzed the frequency and destination of travel to regions lying at an altitude of 
> 2,000 m above sea level (Table 6). Overall, IBD patients experiencing flare-up episodes 
had more frequently traveled to regions lying at an altitude of > 2,000 m above the sea level 
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when compared to IBD patients in remission (13/52 vs. 4/51, p = 0.019). The Swiss Alps 
were the most common travel destination. 
      
DISCUSSION 
     Our study is the first to demonstrate that aircraft travel and journeys to regions at an 
altitude of > 2,000 m above sea level are risk factors for flare-ups in IBD patients. During a 
one-year observation period, patients experiencing flare-up episodes were more likely to 
have traveled by aircraft and/or to have journeyed to regions lying at an altitude of > 2,000 
m above the sea level within four weeks of occurrence of a flare when compared with IBD 
patients in remission. We believe that these data are of particular importance in an era when 
international travel has become increasingly common, and people more than ever tend to 
use air travel as a preferred mode of transportation.  
     In a retrospective study, Soonawala et al. interviewed 277 IBD patients that traveled 
abroad within five years prior to the interview date. Sixty-two percent of patients reported 
that IBD limited their choice of travel destinations.26 Such restrictions are often self-imposed 
stemming from a fear of occurrence of disease flare-up episodes or concerns over other 
travel-related health hazards. Indeed, the present study demonstrates for the first time that 
IBD patients are at an increased risk of experiencing flares soon after flying or traveling to 
regions at an altitude of > 2,000 m above sea level. Despite the impact on patients’ quality 
of life, there are hitherto no studies investigating the risk of developing IBD flares in patients 
undertaking flights or travelling to high-altitude regions. While the data on risk of travel for 
patients with IBD are scarce, Soonawala et al. documented that 19 % (54 of 227) of IBD 
patients had a self-reported exacerbation of IBD within two months of travel, and 24 % of 
patients attributed the exacerbation to the recent travel. It has to be taken into account that 
these findings are based on patient-reported outcomes over a 5-year time period, and 
systematic exclusion of infectious agents as a factor potentially responsible for the 
occurrence of a new flare-up episode was not carried out. Ben-Horin et al. performed a 
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retrospective, case-controlled study of 222 patients with IBD and 224 healthy individuals that 
took 523 and 576 trips, respectively.27 The authors reported that IBD patients had a higher 
rate of illness in comparison to control patients, while traveling to industrialized countries, 
but not to developing or tropical regions.28 These observations cannot be compared to the 
results of our study since evaluation of whether flights or journeys to regions lying at an 
altitude of > 2,000 m above the sea level also represent risk factors for IBD flare-ups was 
not performed. Of note, Ben-Horin et al. have reported that 16 % of IBD patients 
experienced flare-up episodes within 3 months of returning from trips, whereas 40.4 % of 
IBD patients described in our study reported on such episodes within 4 weeks of travel. Our 
inclusion of patients who not only traveled by airplane (which is equivalent to exposure to 
oxygen levels typically observed in regions lying at altitudes of 2,000 - 2,500 m above the 
sea level) but also might have visited regions lying at an altitude of > 2,000 m above the sea 
level may be the reason for the observed difference in the occurrence of flares. If data 
obtained from only those patients who undertook aircraft travel are analyzed, the fraction of 
patients (26.9 %) experiencing IBD flare-up episodes within the four weeks of the flight is 
comparable to that reported by Ben-Horin et al. and Soonawala et al. 27,28 
     It is important to mention that the two including centers (Lausanne and Zurich) are 
located on comparable altitudes (Zurich 408 m above sea level and Lausanne 495 m above 
sea level) as the difference in altitude of place of residence may be important in the 
interpretation of our results. Our data demonstrate an association between aircraft 
travel/journeys to regions lying at an altitude of > 2,000 m above the sea level and 
occurrence of IBD flare-up episodes. Potential underlying mechanisms need to be further 
discussed. Tissue hypoxia is known to be associated with upregulation of hypoxia-inducible 
factor HIF-1α which in turn can upregulate inflammation. This suggests that pro-
inflammatory signaling could increase the susceptibility to hypoxia in affected intestinal 
tissues of IBD patients. In a murine dextrane sulfate sodium (DSS)-induced acute colitis 
model, HIF-1α expression correlated with clinical symptoms severity and histologic 
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damage.28 HIF-1α expression triggers transcription of many genes that ameliorate intestinal 
epithelial cell barrier function, including TNFα.12 For example, it has been shown that 
intestinal epithelial cells can adapt to hypoxia and that the HIF system may play a role in this 
type of adaptation.12 A randomized controlled trial in which IBD patients are exposed to 
hypoxic air by the means of a hypoxia altitude stimulation test (HAST) would provide better 
understanding of the link between hypoxia and occurrence of IBD flares. HAST was useful 
in evaluating the necessity of oxygen supplementation for patients with cardio-pulmonary 
limitations during air travel.16 However, this type of study design may not be feasible for IBD 
patients due to ethical reasons in view of the results presented in this manuscript. One 
might hypothesize that increased clinical activity seen after colonoscopy in UC patients 
might be related to short-term hypoxia in sedated patients.29 This study identified factors 
that put patients at greater risk of a post-procedure flare, including use of steroids, and 
those that reduced the risk, including long-term use of thiopurines.30 
     Our study has several strengths and limitations. To the best of our knowledge, this is the 
first study that systematically assessed aircraft travel and stays in regions at an altitude of > 
2,000 m above the sea level as potential triggering factors for IBD flares. The data obtained 
from the group of patients that travelled by aircraft and those obtained from the group that 
stayed in a region lying at an altitude of > 2,000 m above the sea level were combined for 
analysis as hypoxic stress experienced by an individual in either of the situations is 
equivalent to a decrease in PaO2 to levels between 53 - 64 mm Hg. Inhalation of air under 
conditions of decreased PaO2 corresponds to inhalation of a hypoxic air mixture containing 
about 15 - 17 % of oxygen.16 One of the strengths of the current study is the application of 
strict inclusion and exclusion criteria such as requiring confirmation each flare by a physician 
as well as thorough microbiologic work-up of each flare. In general, patients with unstable 
IBD are less likely to travel, which would tend to bias this study toward a null result, making 
the positive result found more remarkable. The retrospective design and relatively small size 
of the population, which included only patients from Switzerland, are limitations of this study. 
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In addition, while the results of this study suggest an association between aircraft 
travel/stays at regions lying at an altitude of > 2,000 m above the sea level and IBD flare-up 
episodes, additional confounding factors, such as travel-related stress or exposure to 
different microbes in food, could have also contributed to observations made in the study. 
To address these limitations, we are currently planning a larger study using a 
decompression chamber that allows evaluating the impact of hypoxic stress onto the 
organism. Furthermore, while mouse models suggest that hypoxia triggers HIF expression 
and TNFα activation, the exact mechanism of how mild hypoxic stress can trigger bowel 
inflammation in humans needs to be elucidated. Finally, despite the close matching between 
the patient characteristics in both groups, systematic differences between these groups 
cannot be excluded. 
     In summary, we found that IBD patients with recent flare-up episodes more frequently 
travelled by aircraft or journeyed to high altitude regions within four weeks of experiencing 
these episode(s) when compared to the group that remained in remission. We conclude that 
flights and stays at an altitude of > 2,000 m above the sea level are a risk factor for IBD 
flare-up episodes. 
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FIGURE LEGENDS  
 
Figure 1:  
Flight destinations in the group of patients with flare-ups (n=14, blue lines) and in the group 
of patients that were in remission (n=4, green lines). 
 
Figure 2: 
Altitude of stays > 2,000 m above the sea level in the group of patients with flare-ups (n=13) 
and in the group of patients that stayed in remission (n=4) during the observation period (the 
interval from September 1st, 2010 to August 31st, 2011). The number above the graft 
represents days of stay at this altitude.  
Figure 3: 
The frequency of aircraft or a high altitude travel (> 2, 000 m above the sea level) in the group of 
patients with flare-ups and in the group of patients that stayed in remission during the 
observation period (the interval from September 1st, 2010 to August 31st, 2011).  
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TABLES 
Table 1: 
Patient characteristics. Abbreviations: NA, not applicable; CD, Crohn’s disease; UC, 
ulcerative colitis; SD, standard deviation. *Kruskal Wallis test. 
Item Remission Flare-up p-value 
Number of patients 51 52 NA 
Diagnosis 
- CD 
- UC 
 
22 (51.2 %) 
29 (48.3 %) 
 
21 (48.8 %) 
31 (51.7 %) 
 
 
0.777 
CD location L1 4 (18.2 %) 
L2 6 (27.3 %) 
L3 11 (50.0 %) 
L4 1 (4.5 %) 
L1 3 (14.3 %) 
L2 5 (23.8 %) 
L3 13 (61.9 %) 
L4 0 
0.768* 
UC location E1 4 (13.7 %) 
E2 9 (31.0 %) 
E3 16 (55.3 %) 
E1 3 (9.7 %) 
E2 12 (38.7 %) 
E3 16 (51.6 %) 
0.806* 
Gender, females 29 (51.8 %) 27 (48.2 %) 0.615 
Age (mean ± SD) 40.2 ± 14.6 37.6 ± 13.4 0.731 
Age in males (mean ± SD) 42.4 ± 13.3 38.2 ± 14.0 0.588 
Age in females  (mean ± SD) 38.5 ± 13.9 37.1 ± 13.1 0.852 
Smoking status 2/51 (3.9 %) 4/52 (7.7 %) 0.414 
Regular sports activities 18/51 20/52 0.739 
Pregnancy 0 0 NA 
Mean number of flare-
ups/year 
0 1.8 ± 1.7 < 0.001 
Mean number of flare-ups in 
CD patients 
0 1.5 ± 1.1 < 0.001 
Mean number of flare-ups in 
UC patients 
0 2.0 ± 1.8 < 0.001 
 
 
Hier noch Einfügen Hb   13.0   13.4   ns
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Table 2: 
Characteristics of the flare-up episodes experienced during the interval from September 1st, 
2010 to August 31st, 2011. Up to 3 flare-ups per patient were recorded. Non-parametric data 
are depicted as median and IQR (interquartile range). Abbreviations: NA, not applicable; 
CD, Crohn’s disease; UC, ulcerative colitis; SD, standard deviation 
 
Item Flare-up 1 
n = 52 
Flare-up 2 
n = 7 
Flare-up 3 
n = 2 
Flare duration in weeks 
(median, IQR) 
5 [2-12] 4 [2-8] 5 [5-5] 
Flare severity 
- mild  
- moderate 
- severe  
 
5 (9.6 %) 
23 (44.2 %) 
24 (46.2 %) 
 
2 (28.6 %) 
4 (57.1 %) 
1 (14.3 %) 
 
0 
1 (50%) 
1 (50%) 
Harvey-Bradshaw Index for 
CD patients (median, IQR) 
13 [11-15] 11 [7-13] 6 [6-6] 
Rachmilewitz Index for UC 
patients (median, IQR) 
9 [5-11] 7 [6-10] 8 [8-8] 
Type of surgery performed as 
a consequence of flare-up 
- bowel resection 
- abscess drainage 
- dilation 
 
 
2 (3.8%) 
1 (1.9%) 
1 (1.9%) 
 
 
0 
0 
0 
 
 
0 
0 
0 
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Table 3:  
Medication history in the group of patients with flare-ups and in the group of patients that 
were in remission during the observation period. Abbreviations: NA, not applicable; CD, 
Crohn’s disease; UC, ulcerative colitis; SD, standard deviation.  
 
Item Remission  Flare-up p-value 
Number of patients 51 52 NA 
Medication in CD patients 
(n = 43) 
- Aminosalicylates 
- Azathioprine / 6-MP 
- Methotrexate 
- Anti-TNF 
- Systemic steroids  
 
 
4/22 (18.2 %) 
15/22 (68.2 %) 
4/22 (18.2 %) 
6/22 (27.3 %) 
0  
 
 
5/21 (23.8 %) 
13/21 (61.9 %) 
2/21 (9.5 %) 
8/21 (38.1 %) 
16/21 (76.2 %) 
 
 
0.650 
0.666 
0.413 
0.449 
< 0.001 
Medication in UC patients 
(n = 60) 
- Aminosalicylates 
- Azathioprine / 6-MP 
- Methotrexate 
- Anti-TNF 
- Systemic steroids 
 
 
17/29 (58.6 %) 
16/29 (55.2 %) 
1/29 (3.4 %) 
4/29 (13.8 %) 
1/29 (3.4 %) 
 
 
16/31 (51.6 %) 
18/31 (58.1 %) 
0 
7/31 (22.6 %) 
19/31 (61.3 %) 
 
 
0.586 
0.821 
0.297 
0.379 
< 0.001 
NSAID intake  7/51 (13.7 %) 10/52 (19.2 %) 0.452 
NSAID intake one month 
prior to flare-up episode 
2/51 (3.9 %) 4/52 (7.7 %) 0.414 
Antibiotic intake one month 
prior to flare-up episode 
2/51 (3.9 %) 4/52  (7.7 %) 0.414 
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Table 4:  
Frequency of flights and/or stays at an altitude of > 2,000 m above the sea level in the group 
of patients with flare-ups and in the group of patients that were in remission during the 
interval from September 1st, 2010 to August 31st, 2011. Abbreviations: NA, not applicable; 
CD, Crohn’s disease; UC, ulcerative colitis; SD, standard deviation. 
 
Item Remission  Flare-up p-value 
Number of patients 51 52 NA 
Flights and/or stay at an altitude 
of > 2,000 m above the sea level 
- all IBD patients 
8/51 (15.7 %) 21/52 (40.4 %) 0.005 
Flights and/or stay at an altitude 
of > 2,000 m above the sea level 
- CD patients  
2/22 (9.1 %) 8/21 (38.1 %) 0.024 
Flights and/or stay at an altitude 
of > 2,000 m above the sea level 
- UC patients 
6/29 (20.7 %) 13/31 (41.9 %) 0.077 
Flights and/or stay at an altitude 
of > 2,000 m above the sea level 
– males 
6/22 (27.3 %) 13/25 (52.0 %) 0.085 
Flights and/or stay at an altitude 
of > 2,000 m above the sea level 
– females 
2/29 (6.9 %) 8/27 (29.6 %) 0.026 
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Table 5:  
Flight frequency and duration in the group of patients with flare-ups and in the group of 
patients that were in remission during the observation period from1st, 2010 to August 31st, 
2011. Abbreviations: NA, not applicable. 
 
Item Remission Flare-up p-value 
Number of patients 51 52 NA 
Flight frequency - all IBD patients  5/51 (9.8 %) 14/52 (26.9 %) 0.025 
Flight frequency - CD patients  2/22 (9.1 %) 5/21 (23.8 %) 0.191 
Flight frequency - UC patients  3/29 (10.3 %) 9/31 (29.0 %) 0.071 
Flight frequency – males 3/22 (13.6 %) 9/25 (36.0 %) 0.079 
Flight frequency - females  2/29 (6.9 %) 5/27 (18.5 %) 0.189 
Number of flights (mean ± SD)  1.75 ± 0.5 1.71 ± 0.5 0.896 
Flight duration (hours, mean ± SD) 4 ± 4.1 6.2 ± 4.2 0.368 
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Table 6:  
Frequency and location of stays at an altitude of > 2,000 m above the sea level in the group 
of patients with flare-ups and in the group of patients that stayed in remission during the 
observation period (the interval from September 1st, 2010 to August 31st, 2011).  
 
Item Remission (n = 51) Flare-up (n = 52) p-value 
Stays at an altitude of > 
2,000 m above the sea 
level - all IBD patients 
4/51 (7.8 %) 13/52 (25 %) 0.019 
Stays at an altitude of > 
2,000 m above the sea 
level - CD patients 
0/22 3/21 (14.3 %) 0.066 
Stays at an altitude of > 
2,000 m above the sea 
level - UC patients  
4/29 (13.8 %) 10/31 (32.3 %) 0.091 
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